| Unique ID issued by UMIN | UMIN000021171 |
|---|---|
| Receipt number | R000024412 |
| Scientific Title | Assessment of feasibility of sentinel node mapping by indocyanine green fluorescence imaging and metastatic diagnosis by one-step nucleic acid amplification in laparoscopic gastric cancer surgery |
| Date of disclosure of the study information | 2016/02/25 |
| Last modified on | 2023/09/07 16:08:57 |
Assessment of feasibility of sentinel node mapping by indocyanine green fluorescence imaging and metastatic diagnosis by one-step nucleic acid amplification in laparoscopic gastric cancer surgery
Assessment of validity of sentinel node mapping by indocyanine green fluorescence imaging in laparoscopic gastric cancer surgery
Assessment of feasibility of sentinel node mapping by indocyanine green fluorescence imaging and metastatic diagnosis by one-step nucleic acid amplification in laparoscopic gastric cancer surgery
Assessment of validity of sentinel node mapping by indocyanine green fluorescence imaging in laparoscopic gastric cancer surgery
| Japan |
Early gastric cancer
| Gastrointestinal surgery |
Malignancy
NO
To assess the clinical availability of the combination of the sentinel node detection by indocyanine green fluorescence imaging and the metastatic diagnosis by one-step nucleic acid amplification in laparoscopic gastric cancer surgery.
Efficacy
Exploratory
identification rate of fluorescent nodes
1)Durations of tracer administration, sentinel node mapping and diagnosis by one-step nucleic acid amplification.
2)Number of detected sentinel nodes
3)Distribution of sentinel nodes
4)Incidence rate of adverse events and postoperative complications
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Diagnosis
| Maneuver |
To detect sentinel nodes, the tracer (indocyanine green solution) is administrated to the submucosa around the primary tumor at the beginning of surgery.
Stained/fluorescent nodes are harvested intracorporeally prior to gastrectomy. Study subjects will be performed gastrectomy according to gastric cancer treatment guideline.
| 20 | years-old | <= |
| Not applicable |
Male and Female
1) age >= 20
2) clinically T1N0M0 gastric cancer
3) single lesion
4) less than 4cm in diameter
5) out of indication for endoscopic resection
6) biopsy from the primary lesion is positive for CK19
7) BMI <=25
8) The patient who give prior concent to join this study
9) the type of biopsy specimen does not matter
1) the past history of gastric resection or the endoscope treatment
2) the case with tumor invading to esophagus or duodenum
3) a pregnant woman, patients having drug (iodo) allergy career or the asthma
4) the case which the physician judged as the inappropriate case to participate in this study
20
| 1st name | Souya |
| Middle name | |
| Last name | Nunobe |
Cancer Institute Hospital, Japanese Foundation for Cancer Research
Gastroenterological surgery
135-8550
3-8-31, Ariake, Koto, Tokyo 135-8550, Japan
03-3520-0111
souya.nunobe@jfcr.or.jp
| 1st name | Koshi |
| Middle name | |
| Last name | Kumagai |
Cancer Institute Hospital, Japanese Foundation for Cancer Research
Gastroenterological surgery
135-8550
3-8-31, Ariake, Koto, Tokyo 135-8550, Japan
03-3520-0111
koshi.kumagai@jfcr.or.jp
Cancer Institute Hospital, Japanese Foundation for Cancer Research
Sysmex Corporation
Other
Cancer Institute Hospital, Japanese Foundation for Cancer Research
3-8-31, Ariake, Koto, Tokyo 135-8550, Japan
03-3520-0111
med.shinsa@jfcr.or.jp
NO
公益財団法人 がん研究会有明病院
| 2016 | Year | 02 | Month | 25 | Day |
Unpublished
Enrolling by invitation
| 2016 | Year | 07 | Month | 12 | Day |
| 2016 | Year | 12 | Month | 28 | Day |
| 2016 | Year | 08 | Month | 01 | Day |
| 2022 | Year | 12 | Month | 31 | Day |
| 2016 | Year | 02 | Month | 24 | Day |
| 2023 | Year | 09 | Month | 07 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000024412